Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion

Abstract

The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

1 .- 29 . (canceled) 
     
     
         30 . A composition for the stimulation of insulin secretion comprising urolithin C and a GLP-1 agonist, wherein said GLP-1 agonist is selected from the group consisting of albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, oxyntomodulin, and semaglutide. 
     
     
         31 . The composition according to  claim 30 , wherein said GLP-1 agonist is oxyntomodulin. 
     
     
         32 . A pharmaceutical formulation for the treatment of diabetes mellitus comprising an effective amount of the composition of  claim 30  in a pharmaceutically acceptable vehicle. 
     
     
         33 . A pharmaceutical formulation for the treatment of diabetes mellitus comprising an effective amount of the composition of  claim 31  in a pharmaceutically acceptable vehicle. 
     
     
         34 . A food product or a nutritional supplement for the stimulation of insulin secretion comprising an effective amount of the composition of  claim 30  and a nutritionally acceptable vehicle. 
     
     
         35 . A food product or a nutritional supplement for the stimulation of insulin secretion comprising an effective amount of the composition of  claim 31  and a nutritionally acceptable vehicle. 
     
     
         36 . A swallowable tablet, chewable tablet, effervescent tablet, capsule, pill, powder, granule, oral solution, oral suspension, sublingual dosage form, or buccal dosage form, comprising the composition of  claim 30  and a carrier that is acceptable for nutritional usage. 
     
     
         37 . A swallowable tablet, chewable tablet, effervescent tablet, capsule, pill, powder, granule, oral solution, oral suspension, sublingual dosage form, or buccal dosage form, comprising the composition of  claim 31  and a carrier that is acceptable for nutritional usage. 
     
     
         38 . A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of  claim 30  for the treatment of a patient chosen from among the group consisting of a prediabetic patient, a patient whose fasting glycemia is comprised between 1 and 1.25 g L −1  and a patient whose post-prandial glycemia is comprised between 1.40 and 1.99 g L −1 . 
     
     
         39 . A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of  claim 31  for the treatment of a patient chosen from among the group consisting of a prediabetic patient, a patient whose fasting glycemia is comprised between 1 and 1.25 g L −1  and a patient whose post-prandial glycemia is comprised between 1.40 and 1.99 g L −1 . 
     
     
         40 . A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of  claim 30  for the treatment of a diabetic patient, a patient whose fasting glycemia is equal or superior to 1.26 g·L −1  and a patient whose post-prandial glycemia is equal or superior to 2 g·L −1 . 
     
     
         41 . A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of  claim 31  for the treatment of a diabetic patient, a patient whose fasting glycemia is equal or superior to 1.26 g·L −1  and a patient whose post-prandial glycemia is equal or superior to 2 g·L −1 . 
     
     
         42 . A combination product comprising the components of the composition of  claim 30 , provided for simultaneous, separate or sequential use. 
     
     
         43 . A combination product comprising the components of the composition of  claim 31 , provided for simultaneous, separate or sequential use. 
     
     
         44 . A method for treating type 2 diabetes comprising administering to a mammal in need thereof an effective amount of the composition of  claim 30 . 
     
     
         45 . A method for treating type 2 diabetes comprising administering to a mammal in need thereof an effective amount of the composition of  claim 31 .